Perspectives on the combination of radiotherapy and targeted therapy with DNA repair inhibitors in the treatment of pancreatic cancer

Benefit of Surveillance for Pancreatic Cancer in High-Risk Individuals: Outcome of Long-Term Prospective Follow-Up Studies From Three European Expert Centers

(2016) Hans Vasen et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I study of olaparib plus gemcitabine in patients with advanced solid tumours and comparison with gemcitabine alone in patients with locally advanced/metastatic pancreatic cancer

(2015) J. Bendell et al.   ANNALS OF ONCOLOGY

Phase I study of LY2603618, a CHK1 inhibitor, in combination with gemcitabine in Japanese patients with solid tumors

(2015) Toshihiko Doi et al.   ANTI-CANCER DRUGS

Increased in vitro and in vivo sensitivity of BRCA2-associated pancreatic cancer to the poly(ADP-ribose) polymerase-1/2 inhibitor BMN 673

(2015) Alexandra-Zoe Andrei et al.   CANCER LETTERS

A multicentre comparative prospective blinded analysis of EUS and MRI for screening of pancreatic cancer in high-risk individuals

(2015) F Harinck et al.   GUT

LY2603618, a selective CHK1 inhibitor, enhances the anti-tumor effect of gemcitabine in xenograft tumor models

(2015) Darlene Barnard et al.   INVESTIGATIONAL NEW DRUGS

Phase I Dose-Escalation Trial of Checkpoint Kinase 1 Inhibitor MK-8776 As Monotherapy and in Combination With Gemcitabine in Patients With Advanced Solid Tumors

(2015) Adil I. Daud et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors

(2015) Khanh Do et al.   JOURNAL OF CLINICAL ONCOLOGY

Olaparib Monotherapy in Patients With Advanced Cancer and a GermlineBRCA1/2Mutation

(2015) Bella Kaufman et al.   JOURNAL OF CLINICAL ONCOLOGY

Abstract A175: A phase 1 study of a novel inhibitor of protein phosphatase 2A alone or in combination with docetaxel

(2015) Vincent Chung et al.   MOLECULAR CANCER THERAPEUTICS

LY2606368 Causes Replication Catastrophe and Antitumor Effects through CHK1-Dependent Mechanisms

(2015) C. King et al.   MOLECULAR CANCER THERAPEUTICS

Whole genomes redefine the mutational landscape of pancreatic cancer

(2015) Nicola Waddell et al.   NATURE

The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eµ-MYC driven B-cell lymphoma

(2015) Mike I. Walton et al.   Oncotarget

Sensitization of Pancreatic Cancers to Gemcitabine Chemoradiation by WEE1 Kinase Inhibition Depends on Homologous Recombination Repair

(2015) Tasneem Kausar et al.   NEOPLASIA

Gradual Telomere Shortening and Increasing Chromosomal Instability among PanIN Grades and Normal Ductal Epithelia with and without Cancer in the Pancreas

(2015) Yoko Matsuda et al.   PLoS One

DNA-PKcs is important for Akt activation and gemcitabine resistance in PANC-1 pancreatic cancer cells

(2014) Hao Hu et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

PARP inhibition and the radiosensitizing effects of the PARP inhibitor ABT-888 in in vitrohepatocellular carcinoma models

(2014) Clément Guillot et al.   BMC CANCER

Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors

(2014) Edward Sausville et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Abstract 3343: The pre-clinicalin vitroandin vivoactivity of AZD6738: A potent and selective inhibitor of ATR kinase.

(2014) Sylvie M. Guichard et al.   CANCER RESEARCH

Oncogene-induced reactive oxygen species fuel hyperproliferation and DNA damage response activation

(2014) M Ogrunc et al.   CELL DEATH AND DIFFERENTIATION

Gemcitabine and CHK1 Inhibition Potentiate EGFR-Directed Radioimmunotherapy against Pancreatic Ductal Adenocarcinoma

(2014) F. Al-Ejeh et al.   CLINICAL CANCER RESEARCH

Combined Inhibition of Wee1 and PARP1/2 for Radiosensitization in Pancreatic Cancer

(2014) D. Karnak et al.   CLINICAL CANCER RESEARCH

Familial pancreatic cancer: genetic advances

(2014) A. K. Rustgi   GENES & DEVELOPMENT

Elevated DNA damage response in pancreatic cancer

(2014) Michael Osterman et al.   HISTOCHEMISTRY AND CELL BIOLOGY

Radiosensitization of Pancreatic Cancer Cells In Vitro and In Vivo through Poly (ADP-ribose) Polymerase Inhibition with ABT-888

(2014) Richard Tuli et al.   Translational Oncology

Phase I, dose-escalation study of AZD7762 alone and in combination with gemcitabine in Japanese patients with advanced solid tumours

(2013) Takashi Seto et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Poly (ADP-ribose) polymerase inhibitor LT-626: Sensitivity correlates with MRE11 mutations and synergizes with platinums and irinotecan in colorectal cancer cells

(2013) Lisa A. McPherson et al.   CANCER LETTERS

Sensitization of Pancreatic Cancer to Chemoradiation by the Chk1 Inhibitor MK8776

(2013) C. G. Engelke et al.   CLINICAL CANCER RESEARCH

Inhibition of Protein Phosphatase 2A Radiosensitizes Pancreatic Cancers by Modulating CDC25C/CDK1 and Homologous Recombination Repair

(2013) D. Wei et al.   CLINICAL CANCER RESEARCH

ATM Kinase Inhibition Preferentially Sensitizes p53-Mutant Glioma to Ionizing Radiation

(2013) L. Biddlestone-Thorpe et al.   CLINICAL CANCER RESEARCH

BMN 673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair Deficiency

(2013) Y. Shen et al.   CLINICAL CANCER RESEARCH

In Vitro and In Vivo Enhancement of Chemoradiation Using the Oral PARP Inhibitor ABT-888 in Colorectal Cancer Cells

(2013) Joseph W. Shelton et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Adjuvant Chemotherapy With Gemcitabine and Long-term Outcomes Among Patients With Resected Pancreatic Cancer

(2013) Helmut Oettle et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Discovery of 4-{4-[(3R)-3-Methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-yl}-1H-indole (AZ20): A Potent and Selective Inhibitor of ATR Protein Kinase with Monotherapy in Vivo Antitumor Activity

(2013) Kevin M. Foote et al.   JOURNAL OF MEDICINAL CHEMISTRY

Adjuvant treatments for resected pancreatic adenocarcinoma: a systematic review and network meta-analysis

(2013) Wei-Chih Liao et al.   LANCET ONCOLOGY

Preclinical Evaluation of a Novel ATM Inhibitor, KU59403, In Vitro and In Vivo in p53 Functional and Dysfunctional Models of Human Cancer

(2013) M. A. Batey et al.   MOLECULAR CANCER THERAPEUTICS

PARP1 Is Overexpressed in Nasopharyngeal Carcinoma and Its Inhibition Enhances Radiotherapy

(2013) Jeremy P.H. Chow et al.   MOLECULAR CANCER THERAPEUTICS

Combining PARP-1 Inhibition and Radiation in Ewing Sarcoma Results in Lethal DNA Damage

(2013) Hae-June Lee et al.   MOLECULAR CANCER THERAPEUTICS

Combination Drug Scheduling Defines a "Window of Opportunity" for Chemopotentiation of Gemcitabine by an Orally Bioavailable, Selective ChK1 Inhibitor, GNE-900

(2013) E. Blackwood et al.   MOLECULAR CANCER THERAPEUTICS

DNA Double-Strand Break Repair Pathway Choice Is Directed by Distinct MRE11 Nuclease Activities

(2013) Atsushi Shibata et al.   MOLECULAR CELL

Signatures of mutational processes in human cancer

(2013) Ludmil B. Alexandrov et al.   NATURE

Small Molecules, Inhibitors of DNA-PK, Targeting DNA Repair, and Beyond

(2013) David Davidson et al.   Frontiers in Pharmacology

Targeting radiation-resistant hypoxic tumour cells through ATR inhibition

(2012) I M Pires et al.   BRITISH JOURNAL OF CANCER

The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy

(2012) Remko Prevo et al.   CANCER BIOLOGY & THERAPY

Radiosensitization effect of poly(ADP-ribose) polymerase inhibition in cells exposed to low and high liner energy transfer radiation

(2012) Takahisa Hirai et al.   CANCER SCIENCE

EMT and Dissemination Precede Pancreatic Tumor Formation

(2012) Andrew D. Rhim et al.   CELL

Selective radiosensitization of p53 mutant pancreatic cancer cells by combined inhibition of Chk1 and PARP1

(2012) Sean Vance et al.   CELL CYCLE

CCT244747 Is a Novel Potent and Selective CHK1 Inhibitor with Oral Efficacy Alone and in Combination with Genotoxic Anticancer Drugs

(2012) M. I. Walton et al.   CLINICAL CANCER RESEARCH

Racial disparities in treatment for pancreatic cancer and impact on survival: a population-based analysis

(2012) Vinamrata Singal et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Chemosensitization of Cancer Cells by KU-0060648, a Dual Inhibitor of DNA-PK and PI-3K

(2012) J. M. Munck et al.   MOLECULAR CANCER THERAPEUTICS

Optimize radiochemotherapy in pancreatic cancer: PARP inhibitors a new therapeutic opportunity

(2012) Letizia Porcelli et al.   Molecular Oncology

Forced activation of Cdk1 via wee1 inhibition impairs homologous recombination

(2012) M Krajewska et al.   ONCOGENE

Inhibition of Non-Homologous End Joining Repair Impairs Pancreatic Cancer Growth and Enhances Radiation Response

(2012) Ying-Hua Li et al.   PLoS One

The combination of olaparib and camptothecin for effective radiosensitization

(2012) Katsutoshi Miura et al.   Radiation Oncology

Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation

(2012) E Fokas et al.   Cell Death & Disease

CCT241533 Is a Potent and Selective Inhibitor of CHK2 that Potentiates the Cytotoxicity of PARP Inhibitors

(2011) Victoria E. Anderson et al.   CANCER RESEARCH

MK-1775, a Potent Wee1 Inhibitor, Synergizes with Gemcitabine to Achieve Tumor Regressions, Selectively in p53-Deficient Pancreatic Cancer Xenografts

(2011) N. V. Rajeshkumar et al.   CLINICAL CANCER RESEARCH

Oncogenic stress sensitizes murine cancers to hypomorphic suppression of ATR

(2011) David W. Schoppy et al.   JOURNAL OF CLINICAL INVESTIGATION

Gemcitabine Alone Versus Gemcitabine Plus Radiotherapy in Patients With Locally Advanced Pancreatic Cancer: An Eastern Cooperative Oncology Group Trial

(2011) Patrick J. Loehrer et al.   JOURNAL OF CLINICAL ONCOLOGY

Inhibition of PARP-1 by Olaparib (AZD2281) Increases the Radiosensitivity of a Lung Tumor Xenograft

(2011) J. M. Senra et al.   MOLECULAR CANCER THERAPEUTICS

Context Dependence of Checkpoint Kinase 1 as a Therapeutic Target for Pancreatic Cancers Deficient in the BRCA2 Tumor Suppressor

(2011) H. Hattori et al.   MOLECULAR CANCER THERAPEUTICS

Preclinical Development of the Novel Chk1 Inhibitor SCH900776 in Combination with DNA-Damaging Agents and Antimetabolites

(2011) R. Montano et al.   MOLECULAR CANCER THERAPEUTICS

Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR

(2011) Philip M Reaper et al.   Nature Chemical Biology

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

(2011) Thierry Conroy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Inferior Survival of Advanced Pancreatic Cancer Patients Who Received Gemcitabine-Based Chemotherapy but Did Not Participate in Clinical Trials

(2011) Shih-Hung Yang et al.   ONCOLOGY

Combining ATR Suppression with Oncogenic Ras Synergistically Increases Genomic Instability, Causing Synthetic Lethality or Tumorigenesis in a Dosage-Dependent Manner

(2010) O. Gilad et al.   CANCER RESEARCH

Mechanism of Radiosensitization by the Chk1/2 Inhibitor AZD7762 Involves Abrogation of the G2Checkpoint and Inhibition of Homologous Recombinational DNA Repair

(2010) Meredith A. Morgan et al.   CANCER RESEARCH

Radiosensitization by Chir-124, a selective Chk1 inhibitor: Effects of p53 and cell cycle checkpoints

(2010) Yungan Tao et al.   CELL CYCLE

In vitro and In vivo Radiation Sensitization of Human Tumor Cells by a Novel Checkpoint Kinase Inhibitor, AZD7762

(2010) J. B. Mitchell et al.   CLINICAL CANCER RESEARCH

Therapeutic Potential of Poly(ADP-ribose) Polymerase Inhibitor AG014699 in Human Cancers With Mutated or Methylated BRCA1 or BRCA2

(2010) Yvette Drew et al.   JNCI-Journal of the National Cancer Institute

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

(2010) Andrew Tutt et al.   LANCET

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

(2010) M William Audeh et al.   LANCET

The Preclinical Pharmacology and Therapeutic Activity of the Novel CHK1 Inhibitor SAR-020106

(2010) M. I. Walton et al.   MOLECULAR CANCER THERAPEUTICS

Telomere Shortening Sensitizes Cancer Cells to Selected Cytotoxic Agents: In Vitro and In Vivo Studies and Putative Mechanisms

(2010) Orit Uziel et al.   PLoS One

Widespread activation of the DNA damage response in human pancreatic intraepithelial neoplasia

(2009) Jan-Bart M Koorstra et al.   MODERN PATHOLOGY

Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pancreatic cancer cells

(2009) L. A. Parsels et al.   MOLECULAR CANCER THERAPEUTICS

Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion

(2009) S. E. Golding et al.   MOLECULAR CANCER THERAPEUTICS

NEK11 regulates CDC25A degradation and the IR-induced G2/M checkpoint

(2009) Marina Melixetian et al.   NATURE CELL BIOLOGY

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers

(2009) Peter C. Fong et al.   NEW ENGLAND JOURNAL OF MEDICINE

Inhibition of ATR protein kinase activity by schisandrin B in DNA damage response

(2009) H. Nishida et al.   NUCLEIC ACIDS RESEARCH

Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study

(2008) B. Chauffert et al.   ANNALS OF ONCOLOGY

Replication-Dependent Radiosensitization of Human Glioma Cells by Inhibition of Poly(ADP-Ribose) Polymerase: Mechanisms and Therapeutic Potential

(2008) Fiona A. Dungey et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Fluorouracil vs Gemcitabine Chemotherapy Before and After Fluorouracil-Based Chemoradiation Following Resection of Pancreatic Adenocarcinoma

(2008) William F. Regine et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Telomere shortening is associated with poor prognosis and telomerase activity correlates with DNA repair impairment in non-small cell lung cancer

(2008) Cristina Frías et al.   LUNG CANCER

Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1

(2008) A. Blasina et al.   MOLECULAR CANCER THERAPEUTICS

AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies

(2008) S. D. Zabludoff et al.   MOLECULAR CANCER THERAPEUTICS

A novel poly(ADP-ribose) polymerase inhibitor, ABT-888, radiosensitizes malignant human cell lines under hypoxia

(2008) Stanley K. Liu et al.   RADIOTHERAPY AND ONCOLOGY